June Newsletter               2017
Greetings from the Research Lab! In our bi-monthly publication, we share the latest news  from the field, recent findings from our clinical studies, and stories about  the  people of Napa Medical Research Foundation.
NMRF Board Spotlight: Conrad Hewitt

We are delighted to welcome Conrad Hewitt to the Board of Directors. 

A Napa resident for over 20 years, Mr. Hewitt has been involved in helping hospitals, clinics, educational and financial institutions for many years. He brings extensive leadership experience and financial and community involvement skills to the Foundation. Mr. Hewitt looks forward to helping NMRF expand its mission to deliver leading edge regenerative medical solutions to the Napa Valley and the medical community in general.

During his role as Chief Accountant for the United States Securities and Exchange Commission, Mr. Hewitt and his wife Linda left Napa to live in Washington DC for three years. He continues to speak at government and industry conferences nationally.

Most recently, he served for six years as a Trustee with Queen of the Valley Medical Center, is in his second year with the St. Joseph Health System Northern California and is a director emeritus at Bank of the West.

Mr. Hewitt and his wife enjoy traveling, golfing, wine tasting and entertaining and consider themselves fortunate to be able to give back to the community where they live.

Introducing the new NMRF Research Lab!
We are excited to announce the completion of a new research lab facility dedicated to leading the field in proving the performance capability of key regenerative medicine treatments.  

With the dedicated assistance of biomedical laboratory consultant Ryan Dregalla, PhD, Dregalla Medical Technologies, the NMRF will greatly expand the scope and capacity of Dr Bodor’s research. Located in Suite C of the Wellness Center in Napa, the lab serves to complement current and future clinical studies, provide publication-grade data to support clinical findings, and further innovations in the diagnosis and treatment of orthopedic, musculoskeletal, and neurologic conditions and diseases.  

In addition to the recently acquired fluorescent microscope, the fully functional lab facility houses a state-of-the-art flow cytometer, centrifuge, plate reader and incubator – all of which work in tandem to create sophisticated behavioral and compositional models, enable cell culture processing, and provide critical independence and autonomy for the research team. Each element can be optimized to specifically address and perform in keeping with the parameters and desired outcomes of each investigation.

Under the preliminary direction of Ryan Dregalla, the research team will focus their attention on two areas of study. The first study  focuses on characterizing the way that platelets and leukocytes in platelet rich plasma (PRP) interact with the tissues of the intervertebral disc to better understand how this therapy is used to optimize outcomes in patients with degenerative disc disease. This study will further investigate the role that stem cells derived from bone marrow influence these interactions with the intervertebral disc. The second study is focused on using a novel method to lyse platelets with an unprecedented efficiency and harness their therapeutic intracellular proteins without using techniques that otherwise damage these key factors. This product is intended for be for therapeutic use, and it may be patented and commercialized.

Read the full Article

PRP: History, Mechanism of Action, Preparation and Clinical Applications
By Dr. Marko Bodor, Ryan Dregalla, PhD, and Yvette Uribe, BA

Excerpt from Chapter 8 in the forthcoming publication, Essentials of Regenerative Medicine in Interventional Pain Management.

Platelet Rich Plasma (PRP) was first described for clinical use in 1999 to enhance osseointegration for tooth implants well after specific individual growth factors had already been identified for healing of various wound and injury types. The therapeutic importance of platelets became clear when they became better characterized, acting as reservoirs for a wide array of bioactive factors, growth factors, adhesive proteins, coagulation factors, cytokines and chemokines released in the presence of appropriate stimuli and orchestrated in the progression of wound repair. Hence, it was logical to assume that if platelets and their bioactive factors were concentrated and delivered to an injury site, the healing process could be enhanced and expedited.

Soon after being described for oral surgery, PRP was used in veterinary and sports medicine. In 2006, Mishra and Pavelko reported on PRP as an alternative to surgery for chronic tennis elbow. In the last decade the deleterious effects of corticosteroids on tendons and cartilage have become increasingly more recognized and interest in PRP for the treatment of neuromuscular, musculoskeletal and orthopedic conditions has increased exponentially with over 700 peer-reviewed articles referenced on PubMed in 2016. Many “next generation” platelet products, including platelet-rich fibrin, leukocyte-rich or -poor PRP, platelet lysate, post-platelet degranulation serum and extracts have been developed. 

Read complete chapter here

Current Research Study Updates
Carpometacarpal (CMC) Joint Bone Marrow Aspirate Concentrate (BMAC) Outcome Case Study
Dr. Bodor is initiating the first control study to compare the effects of Bone Marrow Aspirate Concentrate (BMAC) to Platelet-Rich Plasma (PRP) for treatment of conditions affecting the thumb CMC joint. In some cases, Dr. Bodor has treated patients with BMAC instead of PRP and has begun to formulate the hypothesis that BMAC could be more effective. The study will determine how and why BMAC works through a 40 patient randomized control study - the first of its kind in the worl d.
Yvette Uribe, Research Assistant, is currently enrolling patients for this landmark study, please email her or call (707) 492-0313 for more information.
Sever's Disease Study:
40 children have successfully finished the specialized 12-week program with all experiencing marked improvement after the first two weeks of treatment.  A randomized control study is in progress with 4 patients enrolled and the need for 12 more subjects to complete the study.  All patients will ultimately receive the newly developed treatment.
  Dr. Bodor will publish a paper on the Sever's Disease Study
in The American Journal of Sports Medicine
Cervical Facet Study:
  The initial hypothesis stated that use of ultrasound guidance for injections into the cervical facet joints would result in greater accuracy and the delivery of a full dose of biologic agent. The study findings, reflecting a 95 - 100% accuracy rate, were shared and analyzed by Dr, Naveen Murthy of the Mayo Clinic and prove the effectiveness of this minimally invasive, less costly ultrasound-guided cervical facet injection technique.
We anticipate publication of these impressive results by October 2017.
Dr. Bodor delivered a keynote speech at the 26th annual meeting of the American Medical Society for Sports Medicine in San Diego. The AMSSM published an article,  "Innovative Approach to Carpal Tunnel Release Explored during AMSSM Annual Meeting." 

Excerpt from article: 

Dr. Bodor has been a trailblazer in exploring innovative ways to treat carpal tunnel syndrome, one of the most common wrist and upper extremity conditions. He will explore this topic during his presentation titled, “Expanding the Treatment Options for Hand and Wrist Conditions.”

Read fulll article

The 8th Annual gathering of thought-leaders from around the globe to learn from each other, collaborate on projects, and advance the field. Newcomers and professionals learn with the best, share cases, and connect with the orthobiologics community.

Dr. Marko Bodor will present Hands-On Lab featuring Lipaspirate, Bone Marrow Concentrate, & Intraosseous Injections.

Leave with the latest research and standardized protocols from world leaders in the field – PRP, BMC, Lipoaspirate and more. Each lecture will provide leading edge science and clinical pearls with take away points for implementation.

Your copy should address 3 key questions: Who am I writing for? (Audience) Why should they care? (Benefit) What do I want them to do here? (Call-to-Action).

Create a great offer by adding words like "free" "personalized" "complimentary" or "customized." A sense of urgency often helps readers take an action, so think about inserting phrases like "for a limited time only" or "only 7 remaining!"